Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies
Nephrology Dialysis Transplantation · 24.06.2026
DOI: 10.1093/ndt/gfag137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 24.06.2026. Verfasst von Jan Miroslav Hartinger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of Czech Republic, Ministry of Education, Czech Republic.
Abstract (Originalsprache)
Background
Anti-drug antibody (ADA) formation against rituximab (RTX) may affect treatment efficacy, safety and B-cell depletion kinetics, yet data across different immune-mediated diseases remain limited.
Methods
We evaluated ADA formation in 1312 blood samples from 300 patients with various autoimmune systemic and kidney-affecting diseases treated by rituximab (RTX) to describe the formation frequency and titers of ADA.
Results
ADA positivity was found in 54 patients and typically paralleled B-cell reconstitution. ADAs were significantly more frequent in diagnoses with overall worse response to RTX treatment [membranous nephropathy (MN), systemic lupus erythematosus, focal-segmental glomerulosclerosis (FSGS) and other less frequent diagnoses] compared with standard-response diagnoses [ANCA-associated vasculitis (AAV) and minimal change disease]. The pattern of ADA formation differed between diagnoses—in AAV ADAs were usually detected in low titers and transiently, in MN ADA titers were higher and more sustained and in FSGS ADA titers were sometimes unmeasurably high and occurred rather early during the treatment. We were not able to evaluate the interference of ADA formation or their titers with clinical response as some of our patients obtained robust response even after formation of unmeasurably high ADA titers.
Conclusions
ADA formation frequency and titers markedly differ between different autoimmune diseases, therefore the frequency of their formation and their clinical significance should be evaluated separately in patients with different diagnoses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
ORCID-Profile: Jan Miroslav Hartinger
Förderung
- Ministry of Health of Czech Republic
- Ministry of Education, Czech Republic
Zitieren
APA
Hartinger, J. M., Šíma, M., Hrušková, Z., Pilková, A., Francová, I., Posová, H., Ryšavá, R., Jančová, E., Mysliveček, M., Tesař, V., & Slanař, O. (2026). Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag137
Vancouver
Hartinger JM, Šíma M, Hrušková Z, Pilková A, Francová I, Posová H, et al. Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag137
BibTeX
@article{Hartinger2026,
author = {Hartinger, Jan Miroslav and Šíma, Martin and Hrušková, Zdenka and Pilková, Alena and Francová, Irena and Posová, Helena and Ryšavá, Romana and Jančová, Eva and Mysliveček, Marek and Tesař, Vladimír and Slanař, Ondřej},
title = {Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag137}
}
EUVIMED